Cargando…

Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety

Sunitinib and pazopanib are tyrosine kinase inhibitors (TKIs) used as first-line therapy for metastatic renal cell carcinoma (RCC). Although these TKIs are associated with similar survival outcomes, some differences have been reported in their safety profiles. In this work, traditional toxicological...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amaro, Filipa, Pisoeiro, Carolina, Valente, Maria João, Bastos, Maria de Lourdes, Guedes de Pinho, Paula, Carvalho, Márcia, Pinto, Joana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456255/ https://www.ncbi.nlm.nih.gov/pubmed/36077297 http://dx.doi.org/10.3390/ijms23179898

Ejemplares similares

Pharmacometabolomics Applied to Personalized Medicine in Urological Cancers
por: Amaro, Filipa, et al.
Publicado: (2022)

Advances and Perspectives in Prostate Cancer Biomarker Discovery in the Last 5 Years through Tissue and Urine Metabolomics
por: Lima, Ana Rita, et al.
Publicado: (2021)

Impact of Cork Closures on the Volatile Profile of Sparkling Wines during Bottle Aging
por: Amaro, Filipa, et al.
Publicado: (2022)

Volatilomics Reveals Potential Biomarkers for Identification of Renal Cell Carcinoma: An In Vitro Approach
por: Amaro, Filipa, et al.
Publicado: (2020)

The Impact of Different Closures on the Flavor Composition of Wines during Bottle Aging
por: Furtado, Isabel, et al.
Publicado: (2021)

Discovery of Volatile Biomarkers for Bladder Cancer Detection and Staging through Urine Metabolomics
por: Pinto, Joana, et al.
Publicado: (2021)

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
por: Gotink, Kristy J., et al.
Publicado: (2015)

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
por: Iyer, Ridhima, et al.
Publicado: (2017)

A Panel of Urinary Volatile Biomarkers for Differential Diagnosis of Prostate Cancer from Other Urological Cancers
por: Lima, Ana Rita, et al.
Publicado: (2020)

GC-MS Metabolomics Reveals Distinct Profiles of Low- and High-Grade Bladder Cancer Cultured Cells
por: Rodrigues, Daniela, et al.
Publicado: (2019)

Biomarker Discovery in Human Prostate Cancer: an Update in Metabolomics Studies
por: Lima, Ana Rita, et al.
Publicado: (2016)

Discrimination between the human prostate normal and cancer cell exometabolome by GC-MS
por: Lima, Ana Rita, et al.
Publicado: (2018)

GC-MS-Based Endometabolome Analysis Differentiates Prostate Cancer from Normal Prostate Cells
por: Lima, Ana Rita, et al.
Publicado: (2018)

Hepatic Metabolic Derangements Triggered by Hyperthermia: An In Vitro Metabolomic Study
por: Araújo, Ana Margarida, et al.
Publicado: (2019)

Factors involved in treatment preference in patients with renal cancer: pazopanib versus sunitinib
por: Mitchell, Catherine C, et al.
Publicado: (2014)

Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells
por: Santoni, M, et al.
Publicado: (2013)

Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib
por: Fiala, Ondřej, et al.
Publicado: (2021)

Biological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver Injury
por: Maillard, Maud, et al.
Publicado: (2022)

Nuclear Magnetic Resonance metabolomics reveals an excretory metabolic signature of renal cell carcinoma
por: Monteiro, Márcia S., et al.
Publicado: (2016)

GC‐MS metabolomics‐based approach for the identification of a potential VOC‐biomarker panel in the urine of renal cell carcinoma patients
por: Monteiro, Márcia, et al.
Publicado: (2017)

A Rapid and Simple Procedure for the Establishment of Human Normal and Cancer Renal Primary Cell Cultures from Surgical Specimens
por: Valente, Maria João, et al.
Publicado: (2011)

Identification of a biomarker panel for improvement of prostate cancer diagnosis by volatile metabolic profiling of urine
por: Lima, Ana Rita, et al.
Publicado: (2019)

Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom
por: Amdahl, Jordan, et al.
Publicado: (2017)

Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population
por: Isaacsson Velho, Pedro, et al.
Publicado: (2018)

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma
por: Xu, C-F, et al.
Publicado: (2015)

Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series
por: Lipplaa, Astrid, et al.
Publicado: (2016)

Chiral enantioresolution of cathinone derivatives present in “legal highs”, and enantioselectivity evaluation on cytotoxicity of 3,4-methylenedioxypyrovalerone (MDPV)
por: Silva, Bárbara, et al.
Publicado: (2016)

Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma
por: Bianconi, Maristella, et al.
Publicado: (2016)

Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose
por: Westerdijk, Kim, et al.
Publicado: (2020)

Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib
por: MacLean, Elizabeth, et al.
Publicado: (2016)

Metastatic Alveolar Soft Part Sarcoma Responsive to Pazopanib after Progression through Sunitinib and Bevacizumab: Two Cases
por: Read, William L., et al.
Publicado: (2016)

Real-world evidence on first-line treatment for metastatic renal cell carcinoma with non-clear cell and sarcomatoid histologies: are sunitinib and pazopanib interchangeable?
por: Bonadioa, Renata Colombo, et al.
Publicado: (2019)

Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis
por: Que, Yi, et al.
Publicado: (2018)

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
por: Amin, Asim, et al.
Publicado: (2018)

Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?
por: Ucar, Gokhan, et al.
Publicado: (2020)

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
por: Amin, Asim, et al.
Publicado: (2019)

Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib
por: Kim, Myung Soo, et al.
Publicado: (2018)

Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First-Line Setting
por: Nikic, Predrag, et al.
Publicado: (2022)

Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis
por: Vogelzang, Nicholas J., et al.
Publicado: (2017)

Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
por: Guo, Jun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gbe5a4he3npv82mhihhjjo2gan